Abstract: A composition, including (A) a medicinal ingredient, (B) a water-insoluble polymer, (C) a non-volatile base, (D) a volatile solvent, and (E) water. The composition has a viscosity at 25° C. of 1.0 mPa·s or more and 10,000 mPa·s or less. The component (A) contains one or more selected from the group consisting of an anti-inflammatory analgesic component, a local irritation component, a blood circulation promoting component, an antihistamine component, a crude drug component, an antipruritic component, a local anesthetic component, a keratin softening component, and an antibacterial component. A mass ratio [(C)/(B)] of the component (C) to the component (B) in the composition is 0.05 or more and 10 or less, and a mass ratio [(E)/(D)] of the component (E) to the component (D) in the composition is 0.005 or more and 1.0 or less.

Abstract: The one aspect of the present invention aims to provide a novel cloning method for human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), which method is based on culture of dispersed single cells without addition of an apoptotic agent. More specifically, the one aspect of the present invention aims to provide a cloning method for hESCs and hiPSCs based on culture of dispersed single cells utilizing shear stress. The above problem is solved by providing a method for culturing dispersed single pluripotent cells, wherein the dispersed single cells are cultured under laminar flow conditions.

Abstract: This invention relates to novel fluorescent GFPs and BFPs. A novel BFP according to this invention has an F64L mutation as well as a L236R mutation and is provided with improved fluorescence. Furthermore, another BFP has the F64L mutation with the characteristics as described above and other mutations, V163A and S175G, and it possesses markedly improved characteristics in the expression at 37 ° C. in addition to those as described above.

Abstract: This invention relates to novel fluorescent GFPs and BFPs. A novel BFP according to this invention has an F64L mutation as well as a L236R mutation and is provided with improved fluorescence. Furthermore, another BFP has the F64L mutation with the characteristics as described above and other mutations, V163A and S175G, and it possesses markedly improved characteristics in the expression at 37 ° C. in addition to those as described above.

Abstract: The present invention relates a vibration generating motor providing simple and fast assembly, and ready recycling. A motor includes a plurality of rotors around a rotary shaft, a plurality of coil winding portions on respective rotors, and a coil on each respective coil winding portion. At least a two part weight is positioned between selected coil winding portions and has an seperably upper and lower part, allowing weight maximization at low cost while conserving space.

Abstract: The present invention relates a vibration generating motor providing simple and fast assembly, and ready recycling. A motor includes a plurality of rotors around a rotary shaft, a plurality of coil winding portions on respective rotors, and a coil on each respective coil winding portion. At least a two part weight is positioned between selected coil winding portions and has an seperably upper and lower part, allowing weight maximization at low cost while conserving space.

Abstract: This invention relates to novel fluorescent GFPs and BFPS. A novel BFP according to this invention has an F64L mutation as well as a L236R mutation and is provided with improved fluorescence. Furthermore, another BFP has the F64L mutation with the characteristics as described above and other mutations, V163A and S175G, and it possesses markedly improved characteristics in the expression at 37 ° C. in addition to those as described above.

Abstract: This invention relates to novel fluorescent GFPs and BFPs. A novel BFP according to this invention has an F64L mutation as well as a L236R mutation and is provided with improved fluorescence. Furthermore, another BFP has the F64L mutation with the characteristics as described above and other mutations, V163A and S175G, and it possesses markedly improved characteristics in the expression at 37° C. in addition to those as described above.